These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27302248)

  • 1. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
    Krutzke L; Prill JM; Engler T; Schmidt CQ; Xu Z; Byrnes AP; Simmet T; Kreppel F
    J Control Release; 2016 Aug; 235():379-392. PubMed ID: 27302248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
    Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
    Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.
    Ma J; Duffy MR; Deng L; Dakin RS; Uil T; Custers J; Kelly SM; McVey JH; Nicklin SA; Baker AH
    PLoS Pathog; 2015 Feb; 11(2):e1004673. PubMed ID: 25658827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X.
    Matsui H; Sakurai F; Katayama K; Yamaguchi T; Okamoto S; Takahira K; Tachibana M; Nakagawa S; Mizuguchi H
    Biomaterials; 2012 May; 33(14):3743-55. PubMed ID: 22357151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
    Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
    Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.
    Alba R; Bradshaw AC; Coughlan L; Denby L; McDonald RA; Waddington SN; Buckley SM; Greig JA; Parker AL; Miller AM; Wang H; Lieber A; van Rooijen N; McVey JH; Nicklin SA; Baker AH
    Blood; 2010 Oct; 116(15):2656-64. PubMed ID: 20610817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
    Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
    J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.
    Xu Z; Qiu Q; Tian J; Smith JS; Conenello GM; Morita T; Byrnes AP
    Nat Med; 2013 Apr; 19(4):452-7. PubMed ID: 23524342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum.
    Harmon AW; Moitra R; Xu Z; Byrnes AP
    PLoS One; 2018; 13(2):e0192353. PubMed ID: 29401488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
    Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
    Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.
    Sumarheni S; Hong SS; Josserand V; Coll JL; Boulanger P; Schoehn G; Fender P
    Hum Gene Ther; 2014 Apr; 25(4):339-49. PubMed ID: 24512117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic strategy to decrease complement activation with adenoviral therapies.
    Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
    PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo.
    Tian J; Xu Z; Moitra R; Palmer DJ; Ng P; Byrnes AP
    PLoS Pathog; 2022 Sep; 18(9):e1010859. PubMed ID: 36156097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.
    Prill JM; Espenlaub S; Samen U; Engler T; Schmidt E; Vetrini F; Rosewell A; Grove N; Palmer D; Ng P; Kochanek S; Kreppel F
    Mol Ther; 2011 Jan; 19(1):83-92. PubMed ID: 20959811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
    Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
    J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver.
    Croyle MA; Chirmule N; Zhang Y; Wilson JM
    Hum Gene Ther; 2002 Oct; 13(15):1887-900. PubMed ID: 12396620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.
    Bradshaw AC; Parker AL; Duffy MR; Coughlan L; van Rooijen N; Kähäri VM; Nicklin SA; Baker AH
    PLoS Pathog; 2010 Oct; 6(10):e1001142. PubMed ID: 20949078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.
    Kaliberov SA; Kaliberova LN; Hong Lu Z; Preuss MA; Barnes JA; Stockard CR; Grizzle WE; Arbeit JM; Curiel DT
    Virology; 2013 Dec; 447(1-2):312-25. PubMed ID: 24210128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.
    Zaiss AK; Foley EM; Lawrence R; Schneider LS; Hoveida H; Secrest P; Catapang AB; Yamaguchi Y; Alemany R; Shayakhmetov DM; Esko JD; Herschman HR
    J Virol; 2016 Jan; 90(1):412-20. PubMed ID: 26491162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.
    Kalyuzhniy O; Di Paolo NC; Silvestry M; Hofherr SE; Barry MA; Stewart PL; Shayakhmetov DM
    Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5483-8. PubMed ID: 18391209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.